European Biosimilar Regulatory Update | Goodwin
In the past few weeks, the European Commission provided marketing authorization for biosimilars of denosumab and omalizumab, as well as an ophthalmic formulation of bevacizumab.
Source: jdsupra.com
Bio Thera Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bio Thera Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bio Thera Solution Today - Breaking & Trending Today
FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP
On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis...
Source: jdsupra.com
Biosimilars Month in Review: December 2023
The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.
Source: hcplive.com
FDA Approves Bevacizumab Biosimilar Bevacizumab-tnjn for Lung, Colorectal Cancers
The decision was based on both clinical and non-clinical data supporting the biosimilarity of bevacizumab-tnjn (Avzivi), previously named BAT1706.
Source: hcplive.com
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
/PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets,...
Source: prnewswire.com